Rapid Communication

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Anne J. Jääskeläinen, Eliisa Kekäläinen, Hannimari Kallio-Kokko, Laura Mannonen, Elisa Kortela, Olli Vapalahti, Satu Kurkela, Maija Lappalainen

1. Department of Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2. Infectious diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
3. These authors contributed equally to the work

Correspondence: Anne J. Jääskeläinen (annemarjut.jaaskelainen@hus.fi)

Citation style for this article:
Jääskeläinen Anne J., Kekäläinen Eliisa, Kallio-Kokko Hannimari, Mannonen Laura, Kortela Elisa, Vapalahti Olli, Kurkela Satu, Lappalainen Maija. Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Euro Surveill. 2020;25(18):pii=2000603. https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000603

Article submitted on 12 Apr 2020 / accepted on 07 May 2020 / published on 07 May 2020

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease (COVID-19) [1]. At time of writing on 22 April 2020, the COVID-19 pandemic had resulted in approximately 2.5 million reported cases worldwide with over 177,000 deaths [1].

Fast and reliable laboratory diagnostics for SARS-CoV2 [2-4] are important to support the rapid implementation of appropriate public health interventions. In the acute phase of COVID-19, laboratory diagnostics primarily rely on molecular methods [5,6]. In addition, serological assays are now being developed to allow epidemiological assessments through serosurveys, as well as retrospective diagnosis in targeted groups. The need for high quality testing kits suitable for in vitro diagnostics (IVD), automated laboratory equipment and laboratory information systems (LIS) is urgent. LIS, which record, manage, and store data are one of the key elements in reliable diagnostics with high throughput. Here we report on the evaluation of an automated serological screening approach for SARS-CoV-2 IgG and IgA antibodies.

Sample collection for evaluation of SARS-CoV-2 IgG and IgA assays

We evaluated two commercial kits designed to respectively detect SARS-CoV-2 IgG and IgA antibodies in patient samples (CE marked in vitro diagnostic products; SARS-CoV-2 IgG and IgA ELISAs, Euroimmun, Lübeck, Germany; www.euroimmun.com). These commercial immunoassays are based on recombinant structural protein (S1) from SARS-CoV-2 and the S1-based ELISAs have been set up and tested for cross-reactions against other HCoVs [7,8]. In the current study, the kits were used in combination with the automated EUROLabworkstation (Euroimmun) for ELISA analysis with LIS.

To estimate specificity, we retrospectively used a panel of 37 patient sera from 15 male and 22 female patients (median age: 53 years; range: 5-87) collected in 2019 and 2020, which were considered negative for SARS-CoV-2. Among these, 11 serum samples were from patients who had been diagnosed with seasonal human coronaviruses (HCoVs: OC43, NL63, 229E) or other respiratory viruses by nucleic acid tests (NAT). Four of these 11 samples, which originated from patients testing positive for HCoV, had been collected in 2019. The rest were from 2020. The four samples from 2019 were assumed to be SARS-CoV-2 negative patients, while all the samples obtained in 2020 were from patients who had been tested for SARS-CoV-2 nucleic acid and found negative. The remaining 26 of the 37 serum samples originated from patients who had been diagnosed as having adenovirus, enterovirus, influenza A, influenza B, parainfluenza, or respiratory syncytial (RSV) virus infections, through routine IgG antibody testing in 2019. These samples were assumed to be negative for SARS-CoV-2.
### Table 1
Demographic data of COVID-19 patients considered in the study and severity of disease Finland, 2020 (n = 40 patients)

| Disease severity  | ID  | Sex | Proportion of M and F | Age in years | Median age in years (range) |
|-------------------|-----|-----|------------------------|--------------|-----------------------------|
| **Mild**<sup>a</sup> (9/37<sup>b</sup>) | 1   | M   | M: 3/9 F: 6/9          | 68           | 41 (24–68)                  |
|                   | 2   | F   |                        | 32           |                             |
|                   | 4   | F   |                        | 32           |                             |
|                   | 5   | F   |                        | 24           |                             |
|                   | 6   | F   |                        | 50           |                             |
|                   | 12  | F   |                        | 51           |                             |
|                   | 20  | F   |                        | 24           |                             |
|                   | 21  | M   |                        | 59           |                             |
|                   | 28  | M   |                        | 41           |                             |
| **Moderate**<sup>a</sup> (15/37<sup>b</sup>) | 3   | M   |                        | 34           |                             |
|                   | 7   | M   |                        | 77           |                             |
|                   | 8   | M   |                        | 53           |                             |
|                   | 10  | M   |                        | 59           |                             |
|                   | 13  | F   |                        | 56           |                             |
|                   | 15  | M   |                        | 54           |                             |
|                   | 17  | M   |                        | 75           | 56 (30–79)                  |
|                   | 22  | F   |                        | 49           |                             |
|                   | 23  | F   |                        | 50           |                             |
|                   | 26  | F   |                        | 79           |                             |
|                   | 30  | F   |                        | 67           |                             |
|                   | 33  | F   |                        | 30           |                             |
|                   | 35  | M   |                        | 65           |                             |
|                   | 36  | F   |                        | 34           |                             |
|                   | 38  | M   |                        | 60           |                             |
| **Severe**<sup>a</sup> (13/37<sup>b</sup>) | 14  | F   |                        | 43           |                             |
|                   | 16  | M   |                        | 72           |                             |
|                   | 19  | M   |                        | 64           |                             |
|                   | 24  | M   |                        | 50           |                             |
|                   | 25  | M   |                        | 39           |                             |
|                   | 27  | M   |                        | 50           |                             |
|                   | 29  | M   |                        | 71           |                             |
|                   | 31  | M   |                        | 58           |                             |
|                   | 32  | F   |                        | 57           |                             |
|                   | 34  | M   |                        | 66           |                             |
|                   | 37  | F   |                        | 56           |                             |
|                   | 39  | M   |                        | 66           |                             |
|                   | 40  | M   |                        | 45           |                             |
| **Not available**<sup>a</sup> (3/40) | 9   | F   | M: 2/3 F: 1/3          | 33           | 64 (33–77)                  |
|                   | 11  | M   |                        | 64           |                             |
|                   | 18  | M   |                        | 77           |                             |
| **Total (n=40 patients)** | NA  | NA  | M: 23/40 F: 17/40      | NA           | 56 (24–77)                  |

COVID-19: coronavirus disease; F: female; ID: identity; M: male; NA: not applicable.

<sup>a</sup> Symptom severity based on Siddiqi and Mehra (2020, in press) [9].

<sup>b</sup> The denominator is based on 37 patients with information on disease severity.
### Table 2
Results of Euroimmun SARS-CoV-2 IgG and IgA ELISAs on patient sera collected in 2019–2020 and specificity of these assays, Finland, 2020 (n = 37)

| Method (No individuals) | Virus (year) | No samples positive for the virus | SARS-CoV-2 Euroimmun ratio* result (median ratio; range) | Specificity of Euroimmun tests |
|------------------------|--------------|----------------------------------|----------------------------------------------------------|-------------------------------|
|                        |              |                                  | IgG     | IgA     |                                   | IgG | IgA |
| IgG (n = 26 individuals)|              |                                  |         |         |                                   |     |     |
|                        | Influenza A virus (2019) | 26                              | 24 negative (0.25; 0.13–0.76) | 19 negative (0.31; 0.09–0.77) |
|                        | Influenza B virus (2019) | 26                              | 2 inconclusive (1.02 0.96–1.07) | 2 inconclusive (1.05; 1.02–1.07) |
|                        | Parainfluenza virus (2019) | 26                              | 0 positive (0; NA) | 5 positive (5.12; 1.52–7.96) |
|                        | RSV (2019) | 26                              | 24/26   | 19/26   |                                 |     |     |
|                        | Enterovirus (2019) | 25                              | 2 inconclusive (1.02 0.96–1.07) | 2 inconclusive (1.05; 1.02–1.07) |
|                        | Adenovirus (2019) | 24                              | 0 positive (0; NA) | 5 positive (5.12; 1.52–7.96) |

|                        | RSV (2020)b | 1                  | 1 negative (0.36; NA) | 1 negative (2.69; NA) |
|                        | RSV and human bocavirus (2020)b | 1 | 1 negative (0.27; NA) | 1 negative (0.31; NA) |
|                        | Adenovirus (2020)b | 1 | 1 negative (0.20; NA) | 1 negative (0.17; NA) |
|                        | Adeno- and rhinovirus (2020)b | 1 | 1 negative (0.45; NA) | 1 negative (0.35; NA) |

| NAT (n = 11 individuals)| Human coronavirus OC431 (2019; 2020)b  | 5 | 4 negative (0.20; 0.13–0.25) | 3 negative (0.20; 0.13–0.25) |
|                        |                                      |     | 0 inconclusive (NA; NA) | 1 inconclusive (0.09; 0.25) |
|                        |                                      |     | 1 positive (2.54; NA)c | 1 positive (1.22; NA)c |

|                        | Human coronavirus NL63 (2020)b | 1 | 1 negative (0.32; NA) | 1 negative (0.36; NA) |

|                        | Human coronavirus 229E (2020)b | 1 | 1 negative (0.22; NA) | 1 negative (0.33; NA) |

| Overall specificity   | 34/37 (91.9%) | 27/37 (73.0%) |

No: number; NAT: nucleic acid test; RSV: respiratory syncytial virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

* The ratios (between the extinction of the sample and calibrator) are the signals given by the assays. A ratio < 0.8 is considered negative, ≥ 0.8 and < 1.1 inconclusive and ≥ 1.1 positive.

b The patient tested negative for SARS-CoV-2 nucleic acid.

c Of the five samples of human coronavirus OC43, four were collected in 2019 and one was collected in 2020. The sample from 2020 was from a patient, who was tested for SARS-CoV-2 nucleic acid and found negative.

c Same individual from year 2019.

Samples collected in 2019 were assumed to be from individuals who were not or had not been infected with SARS-CoV-2.
To investigate the output of the immunoassays on samples from individuals who had been infected with SARS-CoV-2, we retrospectively collected serum samples from patients, who had been prior diagnosed with COVID-19 by real-time RT-PCRs (RT-qPCR) on nasopharyngeal samples as described by Corman et al. [6]. In total, 47 serum samples from 40 individuals (23 males, 17 females) were included. The median age of the patients was 56 years (range: 24–77 years).

For 37 of these 40 individuals, a list of symptoms was available, enabling to rate their disease severity (Table 1). The demographic characteristics of these patients are shown in Table 1 and their samples were employed to study serological results according to disease severity [9].

Finally, we used immunoassays to investigate 13 sera of probable COVID-19 patients (according to the World Health Organization definition [10]) from February–March 2020, who had tested negative for SARS-CoV-2 by NAT.

Data were collected and samples handled according to research permit HUS/32/2018 (Helsinki University Hospital, Finland).

The specimens were analysed with SARS-CoV-2 IgG and IgA kits (Euroimmun) on the EUROLabworkstation (Euroimmun) platform.

**Specificity of SARS-COV-2 IgG and IgA assays**

From the panel of 37 sera considered negative for SARS-CoV-2, serologically negative results for IgG were found in 34 samples and for IgA in 27 samples, yielding a specificity of 91.9% for IgG and 73.0% for IgA (Table 2). Serum samples from one patient with HCoV OC43 infection showed a cross-reaction, however, cross-reactions were not observed in patients with HCoV 229E or NL63 infection.
Results from confirmed COVID-19 patients

A total of 40 patients, whose serum samples were included in the study, had been diagnosed with COVID-19 by RT-qPCR. One patient with a single sample taken before symptom onset was not further investigated. The IgG and IgA respective Euroimmun ratio values obtained from samples of the remaining 39 patients are shown relative to the time elapsed from the first positive PCR test result in Figure 1. It is notable, that for a patient with mild disease (ID 5) (Table 1), the serum sample was negative by IgG assay even 14 days after the first SARS-CoV-2 PCR-positive results (corresponding to 16 days after onset of symptoms); this sample was nevertheless positive for IgA (Figure 1).

For 14 COVID-19 patients, a serum sample happened to have been collected on the same date as the nasopharyngeal sample used for SARS-CoV-2 RT-qPCR: none of the 14 serum samples showed IgG antibodies, while six showed IgA antibodies (Figure 2). The nasopharyngeal and serum samples were taken at a median of 5 days (range: 1–15) after onset of symptoms. Generally, IgA positivity seemed to be detected earlier than that of IgG and samples appeared more frequently positive with IgA than IgG (Figure 1, Figure 2).

Among the 39 COVID-19 patients screened for antibodies against SARS-CoV-2, IgAs and IgGs were both detected in 13, while IgAs alone were detected in 11, yielding a total of 24 IgA positive patients. The median time after onset of symptoms was 12 days (13 patients range: 5–20 days) for detection of IgGs, and 11 days (24 patients range: 5–20 days) for detection of IgAs (Figure 3).

A total of 37 patients had, in addition to the date of symptom onset, a list of symptoms available, allowing us to categorise the severity of their disease
by COVID-19 as mild, moderate or severe [9] (Table 1, Figure 3). We did not see any clear patterns between the IgG or IgA results and disease severity, however the patient number was low (Figure 3).

Results from probable COVID-19 patients
A number of individuals had returned from a COVID-19 epidemic area in Europe or China and had fever and other symptoms compatible with respiratory infection, leading them to be considered as probable COVID-19 patients, however their NAT on nasopharyngeal samples was negative for SARS-CoV-2 as well as for other respiratory viruses tested (Table 3). For 13 of these patients, concurrent nasopharyngeal and serum samples were available for serological testing: one patient was positive for both IgG and IgA in the serum sample, one patient for IgG alone, and one patient IgA alone (Table 3). No further samples from these patients were available for testing.

Discussion
Our results, albeit based on a small number of samples, showed a higher specificity of SARS-CoV-2 IgG ELISA (91.9%) than SARS-CoV-2 IgA ELISA (73.0%), therefore it is not suggested to use the IgA assay for initial screening. However, our results also indicate that the SARS-CoV-2 IgG ELISA (Euroimmun) with automated analysis and LIS can be used for screening of carefully targeted cohorts. Nevertheless, NAT should remain the method of choice for detection of acute SARS-CoV-2 infection.

In this study, serum samples from one patient with HCoV OC43 infection showed a cross-reaction in the SARS-CoV-2 immunoassays. The total number of HCoV samples was low (n = 7), but results are in line with the data reported by Okba et al. [7] and Amanat et al. [8]. Okba et al. [7] studied the specificity of IgG and IgA SARS-CoV-2 S1 ELISAs (research use only (RUO), Euroimmun) with 203 serum samples including 60 serum samples (taken 2–4 weeks after onset of symptoms) from non-SARS HCoV cases (n = 23 OC43; n = 18 NL63; n = 19 229E). Two HCoV OC43-positive serum samples cross-reacted in IgG and IgA assays, while HCoVs NL63 and 229E did not. In addition, these serum samples were also tested using a non-commercial Middle East Respiratory Syndrome coronavirus (MERS-CoV), S1 IgG ELISA [11] with similar cross-reactive results. Larger studies, including neutralisation assays, will be needed to further assess seroassay performance.

In our study, samples became IgA positive earlier than IgG, while the specificity of the test was lower for IgA. Considering the relatively slow IgG seroconversion, a second convalescent sample is often needed to obtain reliable test results. In acute phase diagnostics, IgA assays could be useful along with IgG in patients presenting with atypical symptoms, or when RT-qPCR repeatedly remains negative in a suspected
case. Nicastri et al. [12] reported a paucisymptomatic case with transient mild conjunctivitis and low fever with fluctuating PCR results. However, IgG response was detected when this case was isolated in the hospital along with a positive PCR result. Haveri et al. [13] reported a patient with mild symptoms seroconverting (IgG) to SARS-CoV-2 in 9 days after onset of symptoms. Okba et al. [7] reported that IgG and IgA kinetics varied between patients with different disease severity. In that study, cases with a more severe disease developed an antibody response sooner and in higher concentrations. In our study, there were only 13 patients of 39 who were IgG positive with a median of 12 days (range: 5–20) after onset of symptoms and all 13 were also positive for IgA antibodies. The median for IgA alone (24 patients of 39) was 11 days (range: 5–20). As patient numbers were low, we cannot say if there was any clear pattern similar to the phenomenon observed by Okba et al. in our study, but we noted one case with mild disease severity (ID 5) who was still IgG negative 16 days after onset of symptoms. However, this should be considered when interpreting the serological results for e.g. patients with mild disease.

Seroepidemiological studies will be very useful in informing public health measures in the coming months. In contrast, when attempting to retrospectively establish diagnosis in clinical settings based on serology, it is of critical importance to carefully preselect patients. Otherwise, the positive predictive value will be extremely low, and thus, not meaningful in the current epidemiological situation.

Acknowledgements

We would like to thank all the personnel in the laboratory to make this evaluation possible during this hectic time with the SARS-CoV-2 epidemic in Finland. Especially we would like to thank (in alphabetical order): Hanna Jarva, Anu Jääskeläinen, Pia Jokela, Raisa Loginov, Satu Suuronen, and Anne Toivonen.

Conflict of interest

None declared.

Authors’ contributions

AJJ: Anne J Jääskeläinen; ELKE: Eliisa Kekäläinen; EKo: Elisa Kortela; HKK: Hannimari Kallio-Kokko; LM: Laura Mannonen; OV: Olli Vapalahti; SKU: Satu Kurkela; ML: Maija Lappalainen.

AJJ carried out the collection of retrospective samples together with HKK. AJJ wrote the manuscript, carried out the IgG and IgA ELISAs and analysed the resulting data. ELKE and EKo collected the data from patient records. SKU and OV reviewed the data with AJJ. HKK, LM, SKU and ML took part in the RT-qPCRs evaluation and in setting up RT-qPCR in the laboratory. HKK, OV, LM, ELKE, Eko, SKU and ML reviewed and modified the manuscript and approved its final version.

References

1. European Centre for Disease Prevention and Control (ECDC). Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – ninth update, 23 April 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf
2. Eurosurveillance Editorial Team. Latest updates on COVID-19 from the European Centre for Disease Prevention and Control. Euro Surveill. 2020;25(6):2002131. PMID: 32070466
3. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic. Geneva: WHO. [Accessed 28 Mar 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

4. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaynard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9):2000178. https://doi.org/10.2807/1560-7917.ES.2020.25.9.2000178 PMID: 32156327

5. World Health Organization (WHO). Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020. Geneva: WHO; 17 Jan 2020.

6. Corman VM, Landt O, Kaiser M, Molenkamp R, Mejier A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045 PMID: 31992387

7. Okba NMA, Muller MA, Li W, Wang C, Geurtsvankessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. preprint doi: 8. Amanat F, Nguyen T, Chronikova V, Strohmeier S, Stadlbauer D, Javier A, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. preprint doi: https://doi.org/10.1101/2020.03.17.20037713

9. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant. 2020;39(5):405-7. https://doi.org/10.1016/j.healun.2020.03.012

10. World Health Organization (WHO). Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Geneva: WHO; 20 Mar 2020. Available from: https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)

11. Okba NMA, Raj VS, Widjaja I, GeurtsvanKessel CH, de Bruin E, Chandler FD, et al. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. Emerg Infect Dis. 2019;25(10):1868-77. https://doi.org/10.3201/eid2510.190051 PMID: 31423970

12. Nicastri E, D’Abramo A, Faggioni G, De Santis R, Mariano A, Lepore L, et al. On Behalf Of Inmi And The Italian Army Covid-Study Groups. Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020. Euro Surveill. 2020;25(11):2000230. https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000230 PMID: 32209164

13. Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25(11):2000266. https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000266 PMID: 32209163

License, supplementary material and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2020.